Metabolic evidence
Tirzepatide and heart failure: what SUMMIT’s combined outcome means
Read SUMMIT’s tirzepatide heart-failure results: the combined endpoint, separate death counts, health-status score and current US label context.
The SlimWithPeps reading room
All peptide articles
Browse every SlimWithPeps article: peptide explanations, research comparisons, safety questions and guides to reading the evidence.
53 articles · Newest first
Metabolic evidence
Semaglutide for MASH: why ESSENCE reported two biopsy answers
Understand ESSENCE’s two liver-biopsy endpoints, the 72-week interim findings and what Wegovy’s accelerated MASH approval does and does not establish.
Skin research
Collagen peptide absorption: what a blood test can tell us
What human blood studies reveal about collagen peptide absorption, and why circulating fragments do not automatically establish skin or joint benefits.
Research explained
Peptide trials: why the placebo group belongs beside the headline
Read peptide trials more clearly: distinguish change from baseline, placebo-group change and the treatment comparison, using STEP 1 as a worked example.
Metabolic evidence
Semaglutide and heart risk: how to read SELECT’s 20% result
Understand SELECT’s 20% cardiovascular result, the absolute event proportions, the combined endpoint and who the semaglutide trial actually studied.
Metabolic evidence
GHRP-6 human research: why two half-lives do not make a treatment plan
Explore the small GHRP-6 human pharmacokinetic study, why distribution and elimination half-lives differ, and why neither establishes a treatment schedule.
Metabolic evidence
Weight regain after tirzepatide: the two starting points in SURMOUNT-4
Understand weight regain after tirzepatide, the two baselines in SURMOUNT-4, and why a percentage of body weight differs from a percentage of weight lost.
Research explained
Are peptides steroids? What the distinction does—and does not—tell you
Peptides and steroids are different chemical categories. Learn why that distinction cannot establish product safety, approval, effectiveness or hormonal effects.
Metabolic evidence
Semaglutide vs liraglutide: reading the STEP 8 comparison
Understand the STEP 8 semaglutide–liraglutide comparison, percentage-point differences, treatment discontinuation and the limits of applying averages.
Research explained
Peptide endotoxin testing: what a result below the limit actually means
Learn how to read peptide endotoxin results, reporting limits, units and method suitability—and why a passing result does not establish sterility.
Metabolic evidence
Tirzepatide and lean mass: how to read the DXA results
Understand tirzepatide’s DXA findings, the difference between lean tissue and muscle, and why percentages of weight loss need careful interpretation.
Research explained
Collagen peptides versus whey: which muscle outcome was tested?
Compare collagen and whey muscle research, from six-day protein synthesis measurements to year-long outcomes, without confusing one result for another.
Metabolic evidence
Tirzepatide and sleep apnea: what SURMOUNT-OSA actually measured
Understand SURMOUNT-OSA’s breathing-event results, the role of PAP in the trials, and what tirzepatide’s sleep-apnea approval does and does not mean.
Metabolic evidence
How oral semaglutide is absorbed: why the formulation matters
Explore how SNAC helps oral semaglutide absorption, what food-effect studies measured, and why tablet evidence cannot validate a different formulation.
Metabolic evidence
Semaglutide and kidney disease: what FLOW’s 24% reduction means
Read FLOW’s semaglutide kidney results, distinguish relative risk from percentage points, and see how new mechanism research fits the clinical evidence.
Research explained
Elamipretide, SS-31 and Forzinity: what the FDA approval covers
Understand what Forzinity’s elamipretide approval covers, the limits of its early trials, and what the new confirmatory study is designed to establish.
Research explained
Collagen peptides for joints: pain relief is a different claim from cartilage repair
Compare collagen joint-pain trials, placebo-adjusted results and registry details to understand why symptom relief does not establish cartilage repair.
Research explained
Peptide immunogenicity: what tirzepatide antibody results actually mean
Understand peptide immunogenicity through tirzepatide trial data: antibody detection, clinical effects, safety findings and limits of cross-drug comparisons.
Skin research
Matrixyl peptides: which ingredient did the wrinkle study actually test?
Learn which peptides original Matrixyl and Matrixyl 3000 contain, what wrinkle trials tested, and how to match a cosmetic claim to its formulation.
Research explained
Oxytocin clinical research: why improvement is not the same as a treatment effect
Read the oxytocin autism trial results and a 2026 placebo analysis, with clear explanations of treatment effects, formulation differences and limits.
Metabolic evidence
Cagrilintide vs CagriSema: which treatment produced the result?
Cagrilintide and CagriSema are different interventions. Learn which trial produced each result, how analyses differ, and what FDA says about cagrilintide.
Metabolic evidence
Survodutide and MASH: improvement is not the same as fibrosis reversal
Read survodutide’s MASH trial accurately: why improvement without worsening fibrosis differs from scar reversal, and what its response rates measure.
Metabolic evidence
Weight regain after semaglutide: what two withdrawal studies tell us
What STEP 1 and STEP 4 found after semaglutide withdrawal, why their percentages differ, and what group averages cannot predict for an individual.
Skin research
Argireline peptide: what the wrinkle studies do—and do not—show
Explore the human Argireline wrinkle trial, skin-penetration research and cosmetic claims, with a clear explanation of what the evidence cannot establish.
Metabolic evidence
GHRP-2 and appetite: what the human studies actually measured
What small human GHRP-2 studies found about appetite, what their meal-intake results cannot prove, and how FDA safety concerns change the context.
Metabolic evidence
Is MK-677 a peptide? Classification, human evidence and the muscle claim
MK-677 is not a peptide. Explore ibutamoren’s human trial evidence, why fat-free mass differs from strength, and its FDA status and safety concerns.
Research explained
PT-141 and Vyleesi: what bremelanotide approval actually covers
Understand Vyleesi’s approved use, the bremelanotide trial outcomes, and why an online PT-141 preparation does not inherit a prescription product’s approval.
Research explained
Kisspeptin human studies: what the new 12-day hormone experiment shows
Explore a 2026 kisspeptin-10 study in healthy men, why timing affected hormone responses, and which fertility and long-term treatment questions remain open.
Skin research
Melanotan II side effects: what case reports can and cannot tell us
Read Melanotan II safety reports in context: serious events, uncertain risk rates, and why an apparent tanning effect does not establish product safety.
Skin research
Afamelanotide FDA approval: why Scenesse is an EPP treatment
Understand Scenesse’s approved EPP indication, the pain-free light-exposure endpoint, and why afamelanotide evidence does not establish a cosmetic tanning use.
Research explained
LL-37 peptide research: what the larger wound-healing trial found
Examine the LL-37 venous-ulcer trial, its overall negative finding and exploratory subgroup result, and why topical research does not validate injected products.
Metabolic evidence
AOD-9604 weight-loss evidence: why the larger trial matters
Explore AOD-9604 weight-loss research, the larger negative obesity trial, and why changes within a treatment group do not prove a treatment effect.
Research explained
Epitalon human studies: telomere findings and the longevity gap
Learn what recent epitalon cell research measured, why telomere changes do not prove longer human life, and why epithalamin is a separate substance.
Research explained
Semax human studies: what a stroke-rehabilitation paper can tell us
Read a Semax stroke-rehabilitation study in context: participant groups, BDNF measurements, functional outcomes and limits on cognitive-enhancement claims.
Research explained
Selank human studies: what an anxiety-drug comparison establishes
Examine a Selank anxiety study comparing 62 patients, the difference between similar results and proven equivalence, and the limits of abstract-only evidence.
Research explained
DSIP sleep research: why the small insomnia trials disagree
Compare two small DSIP insomnia studies, their different sleep outcomes, and why a sleep-inducing name does not establish a reliable insomnia treatment.
Metabolic evidence
Ipamorelin clinical trials: what the bowel-surgery study found
Read the human ipamorelin trial behind the claims: what researchers tested, the nonsignificant result, and why its safety findings need context.
Metabolic evidence
Sermorelin FDA status: the GEREF history explained
Understand the history of GEREF, its withdrawn approvals, and why an FDA finding about withdrawal does not approve a compounded sermorelin product.
Research explained
KPV peptide human studies: what the cell and mouse research means
KPV research includes human-derived cells and mouse colitis models. Learn why these are not human treatment trials and which questions remain open.
Research explained
MOTS-c human studies: exercise biology is not an injection trial
Separate human MOTS-c measurements during exercise from mouse treatment experiments, and understand why neither proves an injectable product benefits people.
Research explained
Thymosin alpha-1 clinical trials: reading the corrected TESTS result
Explore the TESTS sepsis trial of thymosin alpha-1, its published correction, and why an overall result differs from an exploratory subgroup claim.
Metabolic evidence
Compounded semaglutide: what the ingredient name does not tell you
Understand how compounded semaglutide differs from an approved medicine, why salt forms matter, and what to clarify with a prescriber or pharmacist.
Metabolic evidence
Tesamorelin: why its approved indication matters
Tesamorelin has a specific approved medical use. Learn why that differs from a general weight-loss claim and how to read the EGRIFTA WR label.
Research explained
TB-500 vs thymosin beta-4: why the exact molecule matters
TB-500 and full-length thymosin beta-4 are not interchangeable research labels. Learn how to check which molecule a human study actually tested.
Metabolic evidence
CJC-1295 human studies: a hormone response is not a health outcome
Explore what early CJC-1295 trials measured, why increased GH and IGF-1 do not prove clinical benefit, and what safety questions remain.
Skin research
Collagen peptides for skin: how to read a positive trial
A closer look at a collagen-peptide skin trial: the studied formulation, measured outcomes, participant dropouts and limits of a positive result.
Blend comparison
GLOW vs KLOW: ingredients, labels and the evidence
Compare the actual GLOW and KLOW labels, understand what KPV adds, and learn why ingredient studies cannot establish a blend’s clinical benefits.
Research literacy
How to read a peptide COA: purity, identity and sterility
Learn what a peptide COA can show about identity, purity, content and microbiological testing—and how to spot the questions a report leaves unanswered.
Metabolic research
Retatrutide explained: what the trials can tell us
Understand the triple receptor agonist, its investigational status, and the questions to ask about new trial results.
Evidence check
BPC-157: where the human evidence begins—and ends
Why promising experiments, small human reports and established clinical evidence are different things.
Skin science
GHK-Cu for skin: what copper-peptide research actually shows
A closer look at topical copper-peptide evidence, study endpoints, and why skin-care findings do not validate injections.
Clinical studies
Tirzepatide vs semaglutide: reading the comparison fairly
What the SURMOUNT-5 trial found, which population it studied, and why averages are not individual predictions.
The fundamentals
What are peptides? A clear starting point
Peptides connect amino acids, but the word alone tells you little about a product’s purpose, evidence or approval.